Status:

Red

Decision Date:

February 2021

Comments

RED: TA668 Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer.

NHS England commissioned - to be used in line with NHSE commissioning intentions

Red Drug Classifications

• 8. NHS England commissioned – to be used in line with NHSE commissioning intentions

search again